The Importance of Disclosure and Conflicts of Interest

Key Points:

  • Dr. Sprintz weighs in on the latest news of the opioid crisis.
  • McKinsey & Company under fire for conflict of interest with Purdue Pharma and FDA.
  • Disclosure, honesty, and transparency are among the top traits in ethical business.

Possibly one of the hottest topics in the pain and addiction management industry is the opioid crisis, where healthcare providers began prescribing opioids at greater rates in the 1990s with the belief that the product was not addictive. What soon ensued are millions of people who have died, misused, and become addicted to opioids. Now, big pharma companies and those associated are under fire for their work in allegedly covering up the addictive component.

As a subject matter expert in the topic, Founder and CEO of the Sprintz Center for Pain and Recovery, Dr. Michael Sprintz, broke down the latest New York Times article on the consulting group McKinsey & Company’s conflict of interest when working with Purdue Pharma, an opioid manufacturer, and the U.S. Food and Drug Administration (FDA).

While working with these two organizations can be a conflict of interest, the disclosure (or lack thereof) piece is what Dr. Sprintz believes got them in trouble. With Dr. Sprintz working on the FDA advisory committee for analgesic and anesthetic drug products, he is very well-versed in how transparency is a top concern. In fact, before every meeting, the group reveals who they have done business with, and if someone has a conflict of interest, they recuse themselves from the discussion and voting to ensure there is zero impartiality.

So, what’s the real issue here? According to Dr. Sprintz, McKinsey’s employees who consulted Purdue Pharma also advised the FDA on relating regulatory and policy issues, and none of this was disclosed.

This has a deeper issue than what’s on the surface, because it could be a good thing to have someone seeing both sides of the aisle — if done correctly, of course. “It reminds us about the importance of being direct and being open,” explained Dr. Sprintz.

By being honest, the FDA could make the determining factor of what’s acceptable in the relationship, and what’s not. “It’s about honest communication and transparency, and if you have those, you can work through a lot of potential issues and potential conflicts.”

To connect with Dr. Sprintz, email him at michael@drsprintz.com or visit his website.

Follow us on social media for the latest updates in B2B!

Latest

Behind WorkJam's Mission to Improve Retention and Training in Retail
Behind WorkJam’s Mission to Improve Retention and Training in Retail
September 27, 2022
  Steve Kramer, CEO at WorkJam, is a twenty-year veteran in e-commerce. His specialty is finding the gaps in how organizations manage their frontlines. He founded WorkJam in 2014 as a digital Read more
hospital employees M&A Healthcare Advisors
M&A Healthcare Advisors to Premiere Podcast Episode Live September 28th
September 27, 2022
On Wednesday, September 28th at 11 am CT, M&A Healthcare Advisors will host a live premiere of its second M&A Healthcare Insights podcast. The broadcast will feature hosts Mark Thomas and Andre Ulloa and Read more
Hire Education: A Commitment to Talent, a C-Suite Conversation
September 27, 2022
In the Catapult Solutions Group podcast, “Hire Education,” host Daniel Litwin talked with the company’s CEO, Patrick Burke, and its CFO, Alex Anderson, about the creation of the company and how Read more